JPH11507540A - 合成哺乳動物染色体および構築のための方法 - Google Patents
合成哺乳動物染色体および構築のための方法Info
- Publication number
- JPH11507540A JPH11507540A JP9502261A JP50226197A JPH11507540A JP H11507540 A JPH11507540 A JP H11507540A JP 9502261 A JP9502261 A JP 9502261A JP 50226197 A JP50226197 A JP 50226197A JP H11507540 A JPH11507540 A JP H11507540A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- purified
- chromosome
- centromere
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 129
- 210000000415 mammalian chromosome Anatomy 0.000 title claims description 56
- 238000010276 construction Methods 0.000 title abstract description 15
- 108020004414 DNA Proteins 0.000 claims abstract description 586
- 210000000349 chromosome Anatomy 0.000 claims abstract description 311
- 241000576133 Alphasatellites Species 0.000 claims abstract description 169
- 210000002230 centromere Anatomy 0.000 claims abstract description 143
- 239000013598 vector Substances 0.000 claims abstract description 91
- 108020004487 Satellite DNA Proteins 0.000 claims abstract description 89
- 230000014509 gene expression Effects 0.000 claims abstract description 38
- 238000010367 cloning Methods 0.000 claims abstract description 29
- 210000004507 artificial chromosome Anatomy 0.000 claims abstract description 28
- 241000124008 Mammalia Species 0.000 claims abstract description 25
- 230000003252 repetitive effect Effects 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims description 158
- 210000004027 cell Anatomy 0.000 claims description 144
- 108091035539 telomere Proteins 0.000 claims description 117
- 210000004962 mammalian cell Anatomy 0.000 claims description 67
- 102000055501 telomere Human genes 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 210000003411 telomere Anatomy 0.000 claims description 45
- 102100025832 Centromere-associated protein E Human genes 0.000 claims description 39
- 108010031379 centromere protein E Proteins 0.000 claims description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
- 238000000338 in vitro Methods 0.000 claims description 35
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 33
- 230000011278 mitosis Effects 0.000 claims description 31
- 108091008146 restriction endonucleases Proteins 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 108091061960 Naked DNA Proteins 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 15
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 12
- 230000000394 mitotic effect Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 6
- 101710096438 DNA-binding protein Proteins 0.000 claims description 4
- 102000053632 repetitive DNA sequence Human genes 0.000 claims description 2
- 108091035233 repetitive DNA sequence Proteins 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 239000003398 denaturant Substances 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 abstract description 28
- 238000001415 gene therapy Methods 0.000 abstract description 18
- 238000011161 development Methods 0.000 abstract description 6
- 238000001890 transfection Methods 0.000 description 41
- 230000006870 function Effects 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 20
- 230000006798 recombination Effects 0.000 description 17
- 238000005215 recombination Methods 0.000 description 17
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 16
- 210000003917 human chromosome Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000010354 integration Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000002593 Y chromosome Anatomy 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 210000005260 human cell Anatomy 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 8
- 230000008707 rearrangement Effects 0.000 description 8
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000031864 metaphase Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 102000011683 Centromere Protein B Human genes 0.000 description 5
- 108010076305 Centromere Protein B Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108091029865 Exogenous DNA Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000001182 human Y chromosome Anatomy 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 210000002415 kinetochore Anatomy 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 108091060290 Chromatid Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 3
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000010823 Telomere-Binding Proteins Human genes 0.000 description 3
- 108010038599 Telomere-Binding Proteins Proteins 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000004756 chromatid Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 101710110830 Beta-agarase Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101710091417 DNA-binding protein TubR Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699664 Mus caroli Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 208000035199 Tetraploidy Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000024321 chromosome segregation Effects 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000815 hypotonic solution Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- -1 incubation time Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101000995194 Homo sapiens Nebulette Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100034431 Nebulette Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- UUVBYOGFRMMMQL-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca].OP(O)(O)=O UUVBYOGFRMMMQL-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010055793 gabase Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220219006 rs1060501597 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- AWDBHOZBRXWRKS-UHFFFAOYSA-N tetrapotassium;iron(6+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] AWDBHOZBRXWRKS-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/208—Pseudochromosomes, minichrosomosomes of mammalian origin, e.g. minichromosome
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/487,989 US5695967A (en) | 1995-06-07 | 1995-06-07 | Method for stably cloning large repeating units of DNA |
| US08/487,989 | 1995-06-07 | ||
| US08/643,554 US6348353B1 (en) | 1995-06-07 | 1996-05-06 | Artificial mammalian chromosome |
| US08/643,554 | 1996-05-06 | ||
| PCT/US1996/010248 WO1996040965A1 (en) | 1995-06-07 | 1996-06-07 | Synthetic mammalian chromosome and methods for construction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11507540A true JPH11507540A (ja) | 1999-07-06 |
| JPH11507540A5 JPH11507540A5 (enExample) | 2004-07-29 |
Family
ID=27049198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9502261A Ceased JPH11507540A (ja) | 1995-06-07 | 1996-06-07 | 合成哺乳動物染色体および構築のための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6348353B1 (enExample) |
| EP (1) | EP0832273A1 (enExample) |
| JP (1) | JPH11507540A (enExample) |
| CN (1) | CN1191574A (enExample) |
| AU (1) | AU724695B2 (enExample) |
| BR (1) | BR9608586A (enExample) |
| CA (1) | CA2224114A1 (enExample) |
| HU (1) | HUP9901072A2 (enExample) |
| IL (1) | IL122414A0 (enExample) |
| MX (1) | MX9709317A (enExample) |
| NZ (1) | NZ311448A (enExample) |
| WO (1) | WO1996040965A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009254379A (ja) * | 1996-04-10 | 2009-11-05 | Biological Research Center Of The Hungarian Academy Of Sciences | 人工染色体、該染色体の使用および人工染色体の製造方法 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869294A (en) * | 1995-06-07 | 1999-02-09 | Case Western Reserve University | Method for stably cloning large repeating DNA sequences |
| US6348353B1 (en) * | 1995-06-07 | 2002-02-19 | Case Western Reserve University | Artificial mammalian chromosome |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| JP4022835B2 (ja) | 1996-08-26 | 2007-12-19 | 株式会社クロモリサーチ | 哺乳類人工染色体 |
| WO1998051790A1 (en) | 1997-05-13 | 1998-11-19 | Amrad Operations Pty. Ltd. | A novel nucleic acid molecule |
| DE19720839B4 (de) * | 1997-05-17 | 2007-08-16 | Dirk Dr. Schindelhauer | Baukastenprinzip-Technologie zur Herstellung von langen, exakten DNA-Konstrukten in vitro, insbesondere für die Herstellung von Konstrukten zur Erzeugung von künstlichen Chromosomen (MAC, mammalian artificial chromosome) aus zwei stabil klonierten DNA-Komponenten und der ditelomerische Vektor-Prototyp PTAT |
| US7235716B2 (en) | 1997-06-03 | 2007-06-26 | Chromatin, Inc. | Plant centromere compositions |
| US6900012B1 (en) | 1997-06-03 | 2005-05-31 | The University Of Chicago | Plant artificial chromosome compositions and methods |
| US7227057B2 (en) | 1997-06-03 | 2007-06-05 | Chromatin, Inc. | Plant centromere compositions |
| US7119250B2 (en) * | 1997-06-03 | 2006-10-10 | The University Of Chicago | Plant centromere compositions |
| US7193128B2 (en) | 1997-06-03 | 2007-03-20 | Chromatin, Inc. | Methods for generating or increasing revenues from crops |
| US6090584A (en) * | 1997-08-21 | 2000-07-18 | University Technologies International Inc. | Baculovirus artificial chromosomes and methods of use |
| DE50015858D1 (de) * | 1999-02-19 | 2010-03-18 | Febit Holding Gmbh | Verfahren zur Herstellung von Polymeren |
| US7989202B1 (en) | 1999-03-18 | 2011-08-02 | The University Of Chicago | Plant centromere compositions |
| WO2001045749A1 (en) * | 1999-12-22 | 2001-06-28 | The Trustees Of The University Of Pennsylvania | Cosmid dna constructs and methods of making and using the same |
| CN100448992C (zh) * | 2001-05-11 | 2009-01-07 | 麒麟医药株式会社 | 含人抗体λ轻链基因的人类人工染色体 |
| US20040210955A1 (en) * | 2001-10-26 | 2004-10-21 | Hidenori Akutsu | Preparation of spermatozoa for ICSI-mediated transgenesis and methods of using the same |
| AU2002953516A0 (en) * | 2002-12-23 | 2003-01-16 | Murdoch Childrens Research Institute | Genetic therapy and genetic modification |
| WO2005010142A2 (en) * | 2003-06-27 | 2005-02-03 | Chromatin, Inc. | Plant centromere compositions |
| WO2005014786A2 (en) * | 2003-08-07 | 2005-02-17 | Athersys, Inc. | Enhanced engineered chromosome formation from alpha satellite with artificially increased density of cenp-b boxes |
| EP1718754A1 (en) * | 2004-02-23 | 2006-11-08 | Chromatin, Inc. | Plants modified with mini-chromosomes |
| ES2679282T3 (es) | 2004-10-22 | 2018-08-23 | Revivicor Inc. | Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena |
| EP1929019A2 (en) * | 2005-09-08 | 2008-06-11 | Chromatin, Inc. | Plants modified with mini-chromosomes |
| US8614089B2 (en) * | 2007-03-15 | 2013-12-24 | Chromatin, Inc. | Centromere sequences and minichromosomes |
| US9593329B2 (en) * | 2007-10-08 | 2017-03-14 | Synthetic Genomics, Inc. | Assembly of large nucleic acids |
| DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
| CA2767724A1 (en) | 2009-07-23 | 2011-01-27 | Chromatin, Inc. | Sorghum centromere sequences and minichromosomes |
| EP3256582A4 (en) * | 2015-02-09 | 2018-06-20 | Edward Perkins | Compositions and methods for monitoring in real-time construction and bioengineering of mammalian synthetic chromosomes |
| CN106318965B (zh) * | 2015-06-26 | 2019-05-07 | 深圳华大生命科学研究院 | 人工半合成染色体的整合方法及含有完整合成染色体的微生物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202256A (en) | 1984-09-13 | 1993-04-13 | Enzon Labs, Inc. | Bioadhesive precursor protein expression vectors |
| US5242808A (en) | 1984-09-13 | 1993-09-07 | Enzon, Inc. | Production of bioadhesive precursor protein analogs by genetically engineered organisms |
| US5049504A (en) | 1986-11-24 | 1991-09-17 | Genex Corporation | Bioadhesive coding sequences |
| US5149657A (en) | 1984-09-13 | 1992-09-22 | Enzon Labs Inc. | Escherichia coli expression vector encoding bioadhesive precursor protein analogs comprising three to twenty repeats of the decapeptide (Ala-Lys-Pro-Ser-Tyr-Pro-Pro-Thr-Tyr-Lys) |
| US5202236A (en) | 1984-09-13 | 1993-04-13 | Enzon Labs Inc. | Method of producing bioadhesive protein |
| FR2593827B1 (fr) | 1986-01-31 | 1989-12-22 | Inst Nat Sante Rech Med | Fragments d'adn utilisables dans des vecteurs pour le maintien hereditaire de genes etrangers a l'etat autonome dans des animaux transgeniques, procede pour leur obtention et applications biologiques |
| US4889806A (en) * | 1987-04-15 | 1989-12-26 | Washington University | Large DNA cloning system based on yeast artificial chromosomes |
| US4889906A (en) * | 1988-11-25 | 1989-12-26 | Monsanto Company | Amine salts of 1,4,2-oxazaphospholidine-4-acetic acid, 2-alkoxy-2-oxides |
| WO1991007496A1 (en) | 1989-11-09 | 1991-05-30 | Allied-Signal Inc. | Cloning and expression of genes encoding for polypeptides comprised of one or more repeating amino acid sequences |
| WO1992007080A1 (en) | 1990-10-17 | 1992-04-30 | Board Of Regents, The University Of Texas System | A eukaryotic episomal dna cloning and expression vector |
| US5288625A (en) | 1991-09-13 | 1994-02-22 | Biologic Research Center Of The Hungarian Academy Of Sciences | Mammalian artificial chromosomes |
| GB9410446D0 (en) * | 1994-05-25 | 1994-07-13 | Cancer Res Campaign Tech | Novel chromosome fragment |
| US5869294A (en) | 1995-06-07 | 1999-02-09 | Case Western Reserve University | Method for stably cloning large repeating DNA sequences |
| US5695967A (en) | 1995-06-07 | 1997-12-09 | Case Western Reserve University | Method for stably cloning large repeating units of DNA |
| US6348353B1 (en) | 1995-06-07 | 2002-02-19 | Case Western Reserve University | Artificial mammalian chromosome |
| US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
-
1996
- 1996-05-06 US US08/643,554 patent/US6348353B1/en not_active Expired - Fee Related
- 1996-06-07 IL IL12241496A patent/IL122414A0/xx unknown
- 1996-06-07 NZ NZ31144896A patent/NZ311448A/xx unknown
- 1996-06-07 EP EP96921588A patent/EP0832273A1/en not_active Withdrawn
- 1996-06-07 AU AU62781/96A patent/AU724695B2/en not_active Ceased
- 1996-06-07 BR BR9608586A patent/BR9608586A/pt unknown
- 1996-06-07 JP JP9502261A patent/JPH11507540A/ja not_active Ceased
- 1996-06-07 WO PCT/US1996/010248 patent/WO1996040965A1/en not_active Ceased
- 1996-06-07 HU HU9901072A patent/HUP9901072A2/hu unknown
- 1996-06-07 CN CN96195654A patent/CN1191574A/zh active Pending
- 1996-06-07 CA CA002224114A patent/CA2224114A1/en not_active Abandoned
-
1997
- 1997-12-01 MX MX9709317A patent/MX9709317A/es not_active IP Right Cessation
-
2001
- 2001-12-19 US US10/023,033 patent/US20030003466A1/en not_active Abandoned
-
2004
- 2004-10-26 US US10/972,786 patent/US20050196837A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009254379A (ja) * | 1996-04-10 | 2009-11-05 | Biological Research Center Of The Hungarian Academy Of Sciences | 人工染色体、該染色体の使用および人工染色体の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996040965A1 (en) | 1996-12-19 |
| US20050196837A1 (en) | 2005-09-08 |
| CN1191574A (zh) | 1998-08-26 |
| HUP9901072A2 (hu) | 1999-07-28 |
| US20030003466A1 (en) | 2003-01-02 |
| AU724695B2 (en) | 2000-09-28 |
| AU6278196A (en) | 1996-12-30 |
| EP0832273A1 (en) | 1998-04-01 |
| CA2224114A1 (en) | 1996-12-19 |
| NZ311448A (en) | 2004-12-24 |
| IL122414A0 (en) | 1998-06-15 |
| MX9709317A (es) | 1998-08-30 |
| BR9608586A (pt) | 1998-12-29 |
| US6348353B1 (en) | 2002-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11507540A (ja) | 合成哺乳動物染色体および構築のための方法 | |
| JP4022835B2 (ja) | 哺乳類人工染色体 | |
| US5817492A (en) | Recombinant DNA viral vector for transfecting animal cells | |
| US20010008025A1 (en) | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes | |
| HUP9904203A2 (hu) | Eljárás hosszú, ismétlődő DNS-szekvenciák stabil klónozására | |
| KR20170096999A (ko) | 신규한 cho 통합 부위 및 이의 용도 | |
| JP2009102331A (ja) | 遍在性クロマチンオープニングエレメント（ｕｃｏｅ）を含むポリヌクレオチド | |
| AU2006235356B2 (en) | Rapid generation of long synthetic centromeric tandem repeats for mammalian artificial chromosome formation | |
| US20140295501A1 (en) | Novel method to load a mammalian artificial chromosome with multiple genes | |
| US7186550B2 (en) | Nucleic acid molecule | |
| JP2003501082A (ja) | ハイブリッド酵母−細菌クローニング系およびその使用 | |
| Grimes et al. | Artificial and engineered chromosomes: developments and prospects for gene therapy | |
| DE60117053T2 (de) | Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten | |
| CN101120093B (zh) | 包含新的调控元件的载体 | |
| Kouprina et al. | From selective full-length genes isolation by TAR cloning in yeast to their expression from HAC vectors in human cells | |
| AU761362B2 (en) | Synthetic mammalian chromosome and methods for construction | |
| JP4164532B2 (ja) | 哺乳類人工染色体 | |
| JP4159620B2 (ja) | 組換えアデノウイルスの製造方法 | |
| JP4642865B2 (ja) | 新規制御エレメントを含むベクター | |
| CA2429724C (en) | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes | |
| JP3713038B2 (ja) | 組換えアデノウイルス | |
| JP4288259B2 (ja) | 動物細胞感染用の組換えｄｎａウイルスベクター | |
| Csonka | Generation of prototype human satellite DNA-based artificial chromosomes | |
| CA3200855A1 (en) | Influenza a-resistant animals having edited anp32 genes | |
| Voet | Design and Characterization of a Chromosomal Vector for Transgenesis in Higher Eukaryotes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070725 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070904 |